Garuda Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $112M
Overview
Developing off-the-shelf, immune-evasive hematopoietic stem cells for universal transplant.
HematologyCell TherapyRegenerative Medicine
Technology Platform
A platform to engineer adult hematopoietic stem cells to be immune-evasive and universally transplantable, using gene editing and synthetic biology approaches.
Funding History
2Total raised:$112M
Venture$50M
IPO$62M
Opportunities
Addressing the critical donor shortage and compatibility issues that limit access to curative stem cell transplants for thousands of patients annually.
Risk Factors
Preclinical scientific risk of achieving durable, safe engraftment of extensively engineered universal donor cells without unforeseen immunological consequences.
Competitive Landscape
Competes with gene-editing biotechs and allogeneic cell therapy companies aiming to create off-the-shelf stem cell products for blood disorders.